Brief: Orion To Discontinue Development Of ODM-105 For Insomnia

Orion Oyj

30/09/2025 11:02

Sept 30 (Reuters) - Orion Oyj ORNBV.HE:

ORION’S PHASE 2 STUDY OF ODM-105 IN INSOMNIA DID NOT MEET PRIMARY GOAL

ORION TO DISCONTINUE DEVELOPMENT OF ODM-105 FOR INSOMNIA.

ODM-105 DID NOT SIGNIFICANTLY IMPROVE INSOMNIA-RELATED SYMPTOMS SUCH AS TIME TO FALL ASLEEP OR SLEEP DURATION COMPARED WITH PLACEBO

Source text: ID:nGNE3Nk1PC

Further company coverage: ORNBV.HE

 (Gdansk Newsroom)

 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))